These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Bajetta E Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604 [No Abstract] [Full Text] [Related]
3. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Eggermont AM Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Kirkwood JM; Tarhini AA; Moschos SJ; Panelli MC Nat Clin Pract Oncol; 2008 Jan; 5(1):2-3. PubMed ID: 18030300 [No Abstract] [Full Text] [Related]
5. Report on the 4th International Conference on the Adjuvant Therapy of Malignant Melanoma held at the Royal College of Physicians, London, UK, 15-16 March 2002. Retsas S; Falkson C; Spitler L Melanoma Res; 2002 Jun; 12(3):A1-4. PubMed ID: 12140389 [No Abstract] [Full Text] [Related]
7. Multidisciplinary treatment of primary melanoma. Yao K; Balch G; Winchester DJ Surg Clin North Am; 2009 Feb; 89(1):267-81, xi. PubMed ID: 19186240 [TBL] [Abstract][Full Text] [Related]
8. Autoimmune phenomena as prognostic markers of response to adjuvant interferon therapy for melanoma. Puente Vázquez J; González Larriba JL Clin Transl Oncol; 2007 Mar; 9(3):125-6. PubMed ID: 17403622 [No Abstract] [Full Text] [Related]
9. New approaches to the systemic treatment of melanoma. Chowdhury S; Vaughan MM; Gore ME Cancer Treat Rev; 1999 Oct; 25(5):259-70. PubMed ID: 10544070 [TBL] [Abstract][Full Text] [Related]
10. Update on the role of adjuvant interferon for high risk melanoma. Agarwala SS; Kirkwood JM Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy in melanoma. Mohr P; Weichenthal M; Hauschild A Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206 [TBL] [Abstract][Full Text] [Related]
18. [Recombinant α-2 interferon in preventing the progression of melanoma]. Korovin SI; Kukushkina MN; Palivets AIu; Fil'chakov FV; Shumilina ES; Ostafĭchuk VV Lik Sprava; 2013 Dec; (8):21-30. PubMed ID: 25726673 [TBL] [Abstract][Full Text] [Related]
19. What can we learn from phase II adjuvant trials in melanoma? Keilholz U; Suciu S; Eggermont AM Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660 [No Abstract] [Full Text] [Related]
20. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]